Table 1.
Clinical features at time of PSC diagnosis
| Baseline feature | Total (n = 56) | 1976–2000 (n = 20) | 2001–2018 (n = 36) | p value |
|---|---|---|---|---|
| Male | 40 (71.43%) | 15 (75.00%) | 25 (69.44%) | 0.65 |
| Age at diagnosis | 33.00 (22.25–47.75) | 37.50 (29.75–51.50) | 29.50 (20.25–47.25) | 0.25 |
| Asymptomatic | 31 (56.36%) | 9 (47.37%) | 22 (61.11%) | 0.32 |
| IBD at diagnosis | 32 (57.14%) | 10 (50.00%) | 22 (61.11%) | |
| Ulcerative colitis | 26 (81.25%) | 8 (80.00%) | 18 (81.82%) | 0.90 |
| Crohn’s disease | 6 (18.75%) | 2 (20.00%) | 4 (18.18%) | |
| PSC-AIH | 3 (5.36%) | 0 | 3 (8.33%) | 0.11 |
| PSC subtype | ||||
| Small duct | 6 (10.71%) | 3 (15.00%) | 3 (8.33%) | 0.44 |
| Intrahepatic | 17 (30.36%) | 3 (15.00%) | 14 (38.89%) | 0.05 |
| Intra and extrahepatic | 33 (58.93%) | 14 (70.00%) | 19 (52.78%) | 0.20 |
| Normal SAP | 10 (17.86%) | 0 | 10 (27.78%) | < 0.01 |
| SAP × ULN | 1.90 (1.16–3.45) | 1.90 (1.36–4.56) | 1.69 (0.92–2.63) | 0.11 |
| Total bilirubin (mg/dL) | 0.70 (0.40–1.60) | 1.20 (0.50–2.30) | 0.60 (0.40–1.30) | 0.07 |
| Albumin (g/dL) | 3.90 (3.5–4.4) | 3.89 (3.27–4.33) | 4.10 (3.60–4.40) | 0.13 |
| Platelet × 103/μL | 280.50 (230.25–333.00) | 281.00 (234.00–336.00) | 279.00 (220.00–331.00) | 0.69 |
| MELD score | 8 (6–10) | 8.5 (7–10) | 7 (6–9) | 0.07 |
| Mayo PSC risk score | − 0.19 (− 1.00 to 0.76) | 0.36 (− 0.57 to 1.55) | − 0.50 (− 1.25 to 0.35) | 0.03 |
| PREsTo | 0.05 (0.03–0.10) | 0.07 (0.03–0.20) | 0.04 (0.03–0.10) | 0.10 |
Continuous variables expressed as median (interquartile range). Categorical variables expressed as number (percentage)
Determined by Chi square testing for categorical variables or Wilcoxon rank sum test for continuous variables
IBD inflammatory bowel disease, PSC-AIH primary sclerosing cholangitis with autoimmune hepatitis, SAP serum alkaline phosphatase, ULN upper limit of normal, MELD model for end-stage liver disease, PRETo PSC risk estimate tool